Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients - PubMed (original) (raw)
Clinical Trial
doi: 10.1016/j.jcv.2004.07.006.
K C Allen Chan, David S Hui, Enders K O Ng, Alan Wu, Rossa W K Chiu, Vincent W S Wong, Paul K S Chan, K T Wong, Eric Wong, C S Cockram, John S Tam, Joseph J Y Sung, Y M Dennis Lo
Affiliations
- PMID: 15494274
- PMCID: PMC7108318
- DOI: 10.1016/j.jcv.2004.07.006
Clinical Trial
Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients
Nelson Lee et al. J Clin Virol. 2004 Dec.
Abstract
Background: The effect of corticosteroid treatment on the viral load of Severe Acute Respiratory Syndrome (SARS) patients is unknown.
Objective: To compare the plasma SARS-CoV RNA concentrations in ribavirin-treated patients who received early hydrocortisone therapy with those who received placebo.
Study design: Serial plasma SARS-CoV RNA concentrations measured in the setting of a prospective, randomized double-blinded, placebo-controlled trial designed to assess the efficacy of "early" (<7 days of illness) hydrocortisone use in previously healthy SARS patients were analyzed. SARS-CoV RNA was quantified using a one-step real-time RT-PCR assay targeting the nucleocapsid gene.
Results: Among 16 non-ICU cases, SARS-CoV RNA was detected in plasma since day 3-4 after fever onset; viral concentration peaked in the first week, which then rapidly declined in the second week of illness. On days 8, 12, 16, and 20, the cumulative proportion of patients with undetectable virus in plasma was 31%, 69%, 92%, and 100%, respectively. Plasma SARS-CoV RNA concentrations in the second and third week of illness were significantly higher in patients who received initial hydrocortisone treatment (n = 9), as compared to those who received placebo (n = 7)(AUC; Mann-Whitney, P = 0.023). The median time for SARS-CoV to become undetectable in plasma was 12 days (11-20 days) versus 8 days (8-15 days), respectively.
Conclusion: Our findings suggested "early" corticosteroid treatment was associated with a higher subsequent plasma viral load.
Figures
Similar articles
- Quantitative analysis and prognostic implication of SARS coronavirus RNA in the plasma and serum of patients with severe acute respiratory syndrome.
Ng EK, Hui DS, Chan KC, Hung EC, Chiu RW, Lee N, Wu A, Chim SS, Tong YK, Sung JJ, Tam JS, Lo YM. Ng EK, et al. Clin Chem. 2003 Dec;49(12):1976-80. doi: 10.1373/clinchem.2003.024125. Clin Chem. 2003. PMID: 14633867 Free PMC article. - Detection of severe acute respiratory syndrome coronavirus RNA in plasma during the course of infection.
Wang WK, Fang CT, Chen HL, Yang CF, Chen YC, Chen ML, Chen SY, Yang JY, Lin JH, Yang PC, Chang SC; Members of the SARS Research Group of National Taiwan University College of Medicine-National Taiwan University Hospital. Wang WK, et al. J Clin Microbiol. 2005 Feb;43(2):962-5. doi: 10.1128/JCM.43.2.962-965.2005. J Clin Microbiol. 2005. PMID: 15695719 Free PMC article. - Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) in post-mortem tissues.
Tang JW, To KF, Lo AW, Sung JJ, Ng HK, Chan PK. Tang JW, et al. J Med Virol. 2007 Sep;79(9):1245-53. doi: 10.1002/jmv.20873. J Med Virol. 2007. PMID: 17607787 Free PMC article. - Corticosteroid administration for viral pneumonia: COVID-19 and beyond.
Yang JW, Yang L, Luo RG, Xu JF. Yang JW, et al. Clin Microbiol Infect. 2020 Sep;26(9):1171-1177. doi: 10.1016/j.cmi.2020.06.020. Epub 2020 Jun 27. Clin Microbiol Infect. 2020. PMID: 32603802 Free PMC article. Review. - Severe acute respiratory syndrome vs. the Middle East respiratory syndrome.
Hui DS, Memish ZA, Zumla A. Hui DS, et al. Curr Opin Pulm Med. 2014 May;20(3):233-41. doi: 10.1097/MCP.0000000000000046. Curr Opin Pulm Med. 2014. PMID: 24626235 Review.
Cited by
- Impact of corticosteroids on initiation and half-year durability of humoral response in COVID-19 survivors.
Wang Y, Guo L, Fan G, Han Y, Zhang Q, Ren L, Zhang H, Wang G, Zhang X, Huang T, Wang W, Chen L, Huang L, Gu X, Wang X, Zhong J, Wang Y, Li H, Yu J, Liu Z, Huang C, Cao B, Wang J. Wang Y, et al. Chin Med J Pulm Crit Care Med. 2024 Mar 15;2(1):48-55. doi: 10.1016/j.pccm.2024.02.005. eCollection 2024 Mar. Chin Med J Pulm Crit Care Med. 2024. PMID: 39170961 Free PMC article. - Outpatient glucocorticoid use and COVID-19 outcomes: a population-based study.
Rodríguez-Fernández A, Visos-Varela I, Zapata-Cachafeiro M, Pintos-Rodríguez S, García-Álvarez RM, Herdeiro TM, Piñeiro-Lamas M, Figueiras A, Salgado-Barreira Á; COVIDRUG Group. Rodríguez-Fernández A, et al. Inflammopharmacology. 2024 Aug;32(4):2305-2315. doi: 10.1007/s10787-024-01474-3. Epub 2024 May 2. Inflammopharmacology. 2024. PMID: 38698179 Free PMC article. - A Retrospective and Comparative Analysis of Clinical Outcomes of Kidney Transplant Recipients During First and Second COVID-19 Waves in North-West India.
Bhagat C, Gurnani N, Godara S, Mathur R, Goel A, Meshram HS. Bhagat C, et al. Cureus. 2024 Jan 5;16(1):e51693. doi: 10.7759/cureus.51693. eCollection 2024 Jan. Cureus. 2024. PMID: 38313994 Free PMC article. - Successful treatment of SARS-CoV-2 in an immunocompromised patient with persistent infection for 245 days: A case report.
Overbeck V, Taylor BP, Turcinovic J, Qiu X, Schaeffer B, Seitz S, Curry SR, Hanage WP, Connor JH, Kuppalli K. Overbeck V, et al. Heliyon. 2023 Dec 14;10(1):e23699. doi: 10.1016/j.heliyon.2023.e23699. eCollection 2024 Jan 15. Heliyon. 2023. PMID: 38223743 Free PMC article. - The Therapy of SARS-CoV-2 Infection in Children.
Edwards KM. Edwards KM. J Clin Med. 2023 Dec 25;13(1):120. doi: 10.3390/jcm13010120. J Clin Med. 2023. PMID: 38202127 Free PMC article. Review.
References
- Centers for Disease Control and Prevention. Severe acute respiratory syndrome (SARS) case definition (http://www.cdc.gov/ncidod/sars/casedefinition.htm).
- Ho J.C., Ooi G.C., Mok T.Y. High dose pulse versus non-pulse corticosteroid regimens in severe acute respiratory syndrome. Am. J. Respir. Crit. Care Med. 2003;168(12):1449–1456. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous